Search Results
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
related diseases; increasing awareness of CD19-targeted therapies; and a growing pipeline of investigational drugs such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan
More news about: DelveInsight Business Research, LLP
Aug 27, 2025, 17:31 ET Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight
such as CAR-T therapies (Allogene Therapeutics's Cemacabtagene ansegedleucel, Miltenyi Biomedicine's Zamtocabtagene autoleucel, Galapagos's GLPG5101, Novartis' Rapcabtagene Autoleucel, Lyell/ImmPACT Bio's IMPT-314, and others), monoclonal antibodies (Genmab's GEN3014), and bispecific antibodies
More news about: DelveInsight Business Research, LLP
Aug 05, 2025, 17:31 ET TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight
TYK2 inhibitors market in the coming years. Some of the key TYK2 inhibitors in the pipeline include Brepocitinib, Zasocitinib, ESK-001, GLPG3667, OST-122, NEU-111, and others.In March 2025, Alumis and Kaken Pharmaceutical entered into a collaboration
More news about: DelveInsight Business Research, LLP